Please provide your email address to receive an email when new articles are posted on . Patients treated with guselkumab vs. fumaric acid esters experienced greater improvement in PASI scores. When ...

Guselkumab demonstrated strong efficacy in treating moderate to severe scalp psoriasis, especially in individuals with skin of color, achieving nearly 70% complete scalp clearance by week 48. The ...

Please provide your email address to receive an email when new articles are posted on . Patients who achieved enthesitis resolution were more likely to have improvements in pain and physical function.

Subcutaneous guselkumab showed significant clinical remission and endoscopic response in moderate to severe Crohn's disease, with no added safety concerns. The GRAVITI study supported guselkumab's ...

TREMFYA ® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study, TREMFYA ® ...

*The as observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 96; ...